spacer
home > ebr > spring 2019 > accessing difficult-to- synthesise metabolites in drug development programmes
PUBLICATIONS
European Biopharmaceutical Review

Accessing Difficult-to- Synthesise Metabolites in Drug Development Programmes

Access to major and/or disproportionate metabolites as part of drug development programmes is critical to ensure adherence to regulatory guidelines issued by the EMA and FDA, as well as to comply with internal safety standards within pharmaceutical companies themselves (1-2).

Identification and characterisation of metabolites ensures not only rigorous safety evaluation of significant metabolites, but can also expand patent coverage and reveal superior potency, reduced side effects, or improved physical properties compared to the parent drug.

Multiple options are available for making metabolites through both chemical and biological routes, as discussed by scientists at Abbvie (3) and summarised in Figure 1.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Julia Shanu-Wilson has over 25 years’ experience in the biotechnology and drug discovery industries. Following a BSc and PhD in microbial biochemistry at Imperial College London, UK, Julia worked in the biotech and pharma industries holding research leadership positions with Xenova, Cubist Pharmaceuticals, and TMO. She joined Hypha Discovery in 2013 and is on the management team, leading scientific communications for the company.
spacer
Julia Shanu-Wilson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Protein Therapeutics

Reading Scientific Services Ltd (RSSL)


More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement